Search

Meet a former NYPD officer who is battling a vicious enemy - ovarian cancer - with support from her new wife.

… Friday, June 24, 2016 Summary Vilma Rosario had just been cleared of non-Hodgkin’s lymphoma , a blood cancer, when she was diagnosed with early-stage ovarian cancer . She had already postponed her wedding once before and wasn’t going to let the disease steal her joy a second time. With support from their

Learn how engineering immune cells to metabolize fructose could supercharge them to fight cancer.

… Thursday, February 27, 2025 Immune cells might be reprogrammed to use the body’s fructose — a naturally occurring sugar — as an energy source that supercharges them to fight cancer, researchers at Memorial Sloan Kettering Cancer Center (MSK) have found. The engineered immune cells showed strong anti-tumor

This new era of cancer research investigates how the disease in certain locations interacts with all the body’s systems. Focusing on cancer’s ecosystem promises to reveal lifesaving insights, especially into metastasis.

… Friday, April 1, 2022 When the ambitious effort to sequence all the DNA in the human genome completed its first draft in 2000, scientists and government officials around the world heralded the achievement of the Human Genome Project. “Without a doubt, this is the most important, most wondrous map ever

The routine use of epidural analgesia for patients with non-small cell lung cancer who undergo a minimally invasive lobectomy is not warranted.

… Wednesday, January 8, 2020 The routine use of epidural analgesia for patients with non-small cell lung cancer (NSCLC) who undergo a minimally invasive lobectomy is not warranted, according to the results of our retrospective study published recently in the journal Lung Cancer . We found no differences

不建议对行微创肺叶切除术的非小细胞肺癌患者常规应用硬膜外镇痛。

… Wednesday, January 8, 2020 根据我们近期发表在 《肺癌》杂志（Lung Cancer） 上的回顾性研究结果，不建议对行微创肺叶切除术的非小细胞肺癌 (NSCLC) 患者常规应用硬膜外镇痛。 我们发现，无论有无硬膜外镇痛，行微创肺叶切除术的 I-III 期 NSCLC 患者在术前、手术或病理因素方面均无差异。未进行硬膜外镇痛的患者住院时间为 3 天，相比进行硬膜外镇痛的患者短 1 天。  (1) 我们需要开展一项前瞻性研究来证实这一发现，并确定在该患者人群中使用其他急性术后疼痛管理方法的安全性。目前，我们的证据对这类患者常规使用硬膜外镇痛提出了有力的反驳。 随着微创手术方法在肺癌治疗中越来越普遍

Scientists are learning how estrogen receptor-positive breast cancer evolves to thwart hormonal therapies and are developing ways to stop it.

… Monday, September 10, 2018 Summary Memorial Sloan Kettering scientists have characterized the landscape of genetic changes that estrogen receptor–positive breast cancer cells use to resist hormonal therapies. The findings suggest ways to prevent or reverse this resistance. Estrogen receptor (ER)–positive

Memorial Sloan Kettering Cancer Center (MSK) has been recognized as the best cancer center in the Northeast, the number two hospital for cancer care in the nation, and the number one hospital nationally for urology care by U.S. News & World Report in its annual Best Hospitals listing.

… Tuesday, July 29, 2025 Memorial Sloan Kettering Cancer Center (MSK) has been recognized as the best cancer center in the Northeast, the number two hospital for cancer care in the nation, and the number one hospital nationally for urology care by  U.S. News & World Report  in its annual Best Hospitals

Drug resistance is a formidable challenge in cancer treatment. A drug called enasidenib (Idhifa®) was approved by the US Food and Drug Administration last year for the treatment of people with a form of acute myeloid leukemia (AML) that’s driven by a mutation in the gene IDH2. About 15 percent of people with AML have this mutation. Research led by Memorial Sloan Kettering Cancer Center (MSK) reports that people who take enasidenib can develop resistance to it — in a way never seen before. Enasidenib works differently than most cancer drugs. Rather than killing leukemia cells, it turns them into normal blood cells. The discovery of this unique resistence may lead to more-precise treatments for people with AML in the future.

… Thursday, July 5, 2018 Bottom Line: Drug resistance is a formidable challenge in cancer treatment. A drug called enasidenib (Idhifa ® ) was approved by the US Food and Drug Administration last year for the treatment of people with a form of acute myeloid leukemia (AML) that’s driven by a mutation in

Because cancer is more treatable when it’s caught early, MSK’s new Precision Interception and Prevention initiative focuses on early detection.

… Thursday, February 22, 2018 Summary Cancer is more treatable when it’s caught early. This fact is driving MSK’s new Precision Interception and Prevention initiative. Cancer often begins to form years or even decades before symptoms appear. And for most cancers, the longer they remain undetected, the

A new mechanical ventilator system designed by anesthesiologists and biomedical engineers at Memorial Sloan Kettering Cancer Center (MSK) has the ability to support two intubated patients simultaneously while compensating for variability in each patient’s size, weight, and pulmonary needs.

… Monday, May 4, 2020 A new mechanical ventilator system designed by anesthesiologists and biomedical engineers at Memorial Sloan Kettering Cancer Center (MSK) has the ability to support two intubated patients simultaneously while compensating for variability in each patient’s size, weight, and pulmonary